Share on StockTwits

BioMed Realty Trust (NYSE:BMR) CEO Alan D. Gold sold 26,615 shares of the stock on the open market in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $22.17, for a total transaction of $590,054.55. Following the transaction, the chief executive officer now directly owns 432,562 shares in the company, valued at approximately $9,589,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of BioMed Realty Trust (NYSE:BMR) remained flat at $22.21 during trading on Thursday. 1,082,623 shares of the company’s stock traded hands. BioMed Realty Trust has a 52-week low of $17.90 and a 52-week high of $22.47. The stock has a 50-day moving average of $21.80 and a 200-day moving average of $21.01. The company has a market cap of $4.242 billion and a P/E ratio of 83.81.

BioMed Realty Trust (NYSE:BMR) last announced its earnings results on Tuesday, August 5th. The company reported $0.40 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.36 by $0.04. The company had revenue of $171.16 million for the quarter, compared to the consensus estimate of $160.80 million. During the same quarter last year, the company posted $0.37 earnings per share. BioMed Realty Trust’s revenue was up 7.2% compared to the same quarter last year. On average, analysts predict that BioMed Realty Trust will post $1.52 earnings per share for the current fiscal year.

A number of research firms have recently commented on BMR. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of BioMed Realty Trust in a research note on Monday. They now have a $24.00 price target on the stock, up previously from $23.00. Separately, analysts at Jefferies Group raised their price target on shares of BioMed Realty Trust from $23.00 to $25.00 in a research note on Tuesday, July 22nd. Finally, analysts at MLV & Co
initiated coverage on shares of BioMed Realty Trust in a research note on Friday, June 27th. They set a “hold” rating and a $23.00 price target on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. BioMed Realty Trust currently has a consensus rating of “Buy” and a consensus target price of $23.29.

BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.